Tag:
exenatide
Latest Headlines
Latest Headlines
Blockbuster breakup: Amylin buys out Lilly's exenatide rights in $1.6B deal
The decade-long union of Amylin ( $AMLN ) and Eli Lilly ( $LLY ) on the diabetes front ended in a blockbuster breakup today, with Amylin agreeing to pay Lilly $250 million upfront and up to $1.2 billion
Who's up for a big FDA approval decision in the first half?
Few events can move a biotech stock quite like an FDA decision on a new drug app. And given the agency's rep for somewhat unpredictable behavior, there's no such thing as a sure thing. All of which
New drug class takes center stage at ADA conference
With standard diabetes drugs like Avandia and Actos drawing increasing scrutiny about safety concerns, a new class of diabetes therapy--dubbed GLiPs--is moving much closer toward regulatory approval.
FDA seeks tougher labeling for Byetta after deaths
They warned you once and they'll warn you again. FDA is upping the label ante on Byetta, the diabetes drug that Eli Lilly and Amylin Pharmaceuticals developed and market, following reports of deaths
